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Aims: We investigated whether major gastrectomy influences the plasma exposure
of regorafenib and treatment outcome.
Methods: Efficacy and pharmacokinetic data from 133 gastrointestinal stromal
tumour patients included in a phase III trial were analysed. Patients were subdivided
into 2 groups according to the extent of the gastrectomy (no/nonsignificant gastrec-
tomy and major gastrectomy). Progression‐free survival (PFS) on regorafenib was
measured and regorafenib and its pharmacological active metabolites plasma expo-
sure were measured.
Results: A total of 133 patient were included, of whom 27 underwent major gas-
trectomy. In patients with no/nonsignificant gastrectomy the median PFS was 145
(interquartile range 43–281) days. The PFS in patients with a major gastrectomy
was 172 (interquartile range 57–280) days. Regorafenib pharmacokinetic samples
were collected in 80 patients of which 19 patients with a major gastrectomy and
61 patients with no/nonsignificant gastric surgery. The average ± standard deviation
total concentration of regorafenib including the metabolites M‐2 and M‐5 was
6.9 ± 1.53 μmol/L and 6.7 ± 1.56 μmol/L in patient with major gastrectomy and
no/nonsignificant gastrectomy respectively.
Conclusion: Our study shows that major gastrectomy did not influence plasma
exposure of regorafenib and metabolites. In addition, no difference in PFS between
the subgroups was seen.
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1 | INTRODUCTION
Gastrointestinal stromal tumour (GIST) is 1 of the most common
soft tissue sarcoma subtypes.1 GIST is primarily located in the stom-
ach (56%) followed by the small intestine (32%).2 Imatinib is the
first‐line treatment in patients with unresectable or metastatic GIST
followed by sunitinib and thereafter regorafenib as third‐line
treatment.3
Regorafenib is an oral multikinase inhibitor (TKI) that blocks the
activity of multiple protein kinases, including those involved in the reg-
ulation of oncogenesis (KIT, RET, RAF‐1, BRAF and BRAFV600E),
tumour microenvironment (PDGFRs and FGFRs) and tumour angio-
genesis (VEGFR 1–3 and TIE2).4 Regorafenib is taken once daily with
a low‐fat meal for 3 weeks out of a 4 week cycle.5 Regorafenib is clas-
sified as a Biopharmaceutics Classification System (BCS) type II drug
due to its high permeability and poor solubility independent of
medium.6 To improve the solubility of regorafenib, an amorphous solid
dispersion tablet of regorafenib was developed resulting in a mean rel-
ative bioavailability of 69–83%.6 At doses above 60 mg regorafenib
exposure increases less than dose proportional, suggesting saturated
absorption.7 After regorafenib administration, 3 peaks in plasma con-
centrations were observed at t = 4, 8 and 24 hours indicating that
regorafenib might undergo entrohepatic cycling.7 The 2 main metabo-
lites of regorafenib, M‐2 and M‐5, show equipotent antitumour effi-
cacy and therefore contribute to the pharmacological activity of
regorafenib.8
One of the possible mechanisms that could majorly affect orally
administered TKI exposure is alteration of the pH of the gastrointesti-
nal tract.9,10 Due to the location of the GIST, patients commonly
undergo gastric surgery to remove the primary tumour. In patients
with gastrectomy, the local pH increases due to resection of acid pro-
ducing cells in the stomach, which could affect the dissolution of drugs
that require an acid environment for solubility.11,12 Since only dis-
solved drug can be absorbed, decreased solubility will lead to
decreased drug exposure, which might affect treatment outcome.13
The solubility of regorafenib is claimed to be independent of pH.6
Therefore, it is not expected that gastrectomy, resulting in altered gas-
tric pH, would influence regorafenib solubility. This was confirmed by
de Man et al. who showed that no change in regorafenib exposure
was observed when it was taken with or without esomeprazole, prov-
ing no effect of gastric acid elevating agents.14
However, not only the acid producing cells are removed by gas-
trectomy. It is suggested that transporters such as ABCC4, which are
mainly localized in the stomach, could facilitate drug absorption and
that in patients with major gastrectomy, are also removed.15,16 This
effect was seen in patient using imatinib who underwent gastrectomy
and showed a reduced imatinib exposure of 30% compared to patients
without gastric surgery.17 Imatinib solubility is, like regorafenib, not
pH dependent and not affected by gastric acid elevating agents.18 Fur-
thermore, in a study where patients with gastrectomy were given ima-
tinib together with Coca‐Cola to decrease the pH, no effect on drug
exposure was seen.16 This indicates that mechanisms other than pH
alteration play an important role in oral TKI uptake.
Since the effect of gastrectomy on regorafenib absorption is
unknown and since regorafenib exposure might have consequences
for treatment outcome, we wanted to investigate the effect of major
gastrectomy on regorafenib exposure and progression‐free survival
(PFS) in patients with GIST.
2 | METHODS
2.1 | Study design
In this retrospective analysis, data from the GRID trial were used.19
The GRID trial was a multicentre randomised placebo‐controlled
phase III trial in which 57 hospitals from 17 countries participated. In
the GRID trial 133 participants were randomized to receive an initial
regorafenib dose of 160 mg once daily 3 weeks every 4 weeks. Rego-
rafenib administration was continued until disease progression, occur-
rence of unacceptable toxic effects or withdrawal from the study.
Patients were followed up in the study for a maximum of 18 months.
2.2 | Study subjects
Eligible patients had histological confirmed, metastatic or unresectable
GIST, with failure on at least imatinib and sunitinib. Additional inclu-
sion criteria included: an Eastern Cooperative Oncology Group perfor-
mance status of 0 or 1 and an adequate haematological, hepatic,
cardiac, and renal function. The study was performed in accordance
with Good Clinical Practice and under the ethical principles
established by the Declaration of Helsinki. The protocol was reviewed
and approved by the Institutional Review Board of each participating
institution and informed consent was obtained from each patient.
The GRID trial was registered at Clinical trial.gov, number
NCT01271712. The subanalysis on the existing dataset of Bayer was
What is already known about this subject
• Patients with gastric gastrointestinal stromal tumour
commonly undergo gastric surgery to remove the
primary tumour.
• The solubility of regorafenib is independent of Ph.
• It is suggested that transporters such as ABCC4 could
facilitate drug absorption. In patients with major
gastrectomy these transporters are removed.
What this study adds
• This study demonstrates that neither the response to
regorafenib nor the exposure to regorafenib and its
metabolites changed in patient who underwent
gastrectomy.
• The results of this study confirm that dose alterations are
unnecessary when patients with a gastrectomy are
treated with regorafenib.
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requested by the non‐Bayer affiliated authors of this manuscript and
was reviewed and granted by Bayer.
2.3 | Sampling and bio analysis
Blood samples for pharmacokinetic (PK) assessment of regorafenib
and its active metabolites M‐2 and M‐5 were collected at t = 24 h
after regorafenib intake on day 15 of the first and the second treat-
ment cycle after reaching steady‐state PK. The PK assessment visit
was scheduled after at least 14 days of uninterrupted stable dosing
of study drug. Regorafenib and M‐2 and M‐5, after repeated dosing,
have very flat concentration–time profiles, peak/trough ratio of 1.3,
1.6 and 1.5, respectively.20 Given the low peak–trough fluctuation at
steady state due to the long half‐life of regorafenib and its active
metabolites, the average concentration is an adequate parameter to
describe the extend of exposure to regorafenib and its pharmacologi-
cal active metabolites. The average concentration was calculated
based on the actual dosing of the individual patient and AUC divided
by dosing interval.21
Regorafenib, M‐2 and M‐5 together represent 92.4% of the total
exposure in plasma and at steady state, regorafenib together with its
active metabolites are responsible for the total efficacy. Therefore,
the sum of the regorafenib including M‐2 and M‐5 was used to deter-
mine the effect of gastrectomy on regorafenib efficacy. A validated
liquid chromatography–tandem mass spectrometry method was used
to analyse regorafenib and metabolites M‐2 and M‐5.22
2.4 | Statistical analysis
The gastric surgery status was specified for patients participating in the
study and therefore all patients could be included for the efficacy
analysis. Patients were subdivided into 2 subgroups according to their
previous GI surgery: major gastrectomy and no/nonsignificant
gastrectomy (defined by physicians' judgement). PFS was measured
from the date of randomization until the date of radiological progres-
sion or death. Subjects without tumour progression or death at the time
of analysis were censored at their last date of radiological tumour
assessment. Only a subset of patient PK data were available. These
patients were included in the PK analysis. The statistical analysis on
the existing dataset was done using SAS version 9.2.
2.5 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY,23 and are permanently archived in the Concise Guide to
PHARMACOLOGY 2017/18.24
3 | RESULTS
3.1 | Patient characteristics
A total of 133 patients with metastatic GIST were randomized to
receive regorafenib in the GRID trial, of whom 27 previously
underwent a major gastrectomy for their primary tumour. The other
106 patients served as controls and had no/nonsignificant gastric sur-
gery. Regorafenib PK samples were taken in 80 of the 133 patients, 19
TABLE 1 Patient characteristics
Major
gastrectomy
No or nonsignificant
gastrectomy
No. % No. %
Number of patients 27 106
Age (y)
Median (range) 57 (18–76) 60 (26–82)
Sex
Female 12 44.4 36 34.0
Male 15 55.6 70 66.0
Race
Caucasian 20 74.1 70 66.0
Asian 5 18.5 29 27.4
Unknown 2 7.4 7 6.6
ECOG
0 17 63.0 56 52.8
1 10 37.0 50 47.2
Extent of disease at initial diagnose
Localized 17 63.0 56 52.8
Advanced 2 7.4 5 4.7
Metastatic 8 29.6 44 41.5
Unknown 0 0 1 0.9
Median dose, mg 122.4 146a
aOut of the 106 subjects, 105 subjects received regorafenib.
ECOG, Eastern Cooperative Oncology Group
TABLE 2 Drug related adverse events > grade 2
Major
gastrectomy
No or nonsignificant
gastrectomy
No. % No. %
Any event 14 73.7 49 80.3
Hypertension 6 31.6 24 39.3
Hand–foot syndrome 6 31.6 12 19.7
Diarrhoea 2 10.5 9 14.8
Fatigue 1 5.3 5 8.2
Anorexia 0 0 1 1.6
Rash, macropapullar 1 5.3 2 3.3
Nausea 0 0 1 1.6
Constipation 0 0 1 1.6
ALAT increase 1 5.3 4 6.6
ASAT increase 1 5.3 3 4.9
AP increase 1 5.3 0 0
ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; AP:
alkaline phosphatase
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with major gastrectomy and 61 with no/nonsignificant gastric surgery.
Baseline characteristics including age, sex and extent of disease are
shown in Table 1. Regarding regorafenib related adverse events,
hypertension and hand–foot syndrome were the most present
followed by diarrhoea. All except hand–foot syndrome were equally
present in both groups (Table 2).
3.2 | Effect on PFS
In patients with no/nonsignificant gastrectomy 64 (60%) of the 106
patients experienced progression/death (event) under regorafenib
therapy during study follow up. Of the 27 patients who underwent a
major gastrectomy 17 (63%) patients experienced progression/death
during the study. Patient with no/nonsignificant gastric surgery had
a median PFS of 145 days (interquartile range 43–281) compared to
a median PFS of 172 days (interquartile range 57–280) in patients
with major gastrectomy (Figure 1).
3.3 | Effect on regorafenib plasma exposure
In patients with PK samples available, the geometric mean (including
standard deviation [SD] and range) of the average total concentration
of regorafenib, M‐2 and M‐5 was 6.9 ± SD 1.53 μmol/L (3.73–19.81;
CV% 44.5) and 6.7 ± SD 1.56 μmol/L (2.28–18.48; CV% 46.5) in patient
with major gastrectomy(n = 19) and no/nonsignificant gastrectomy
(n = 61), respectively. In a subanalysis, major gastrectomy was divided
into total gastrectomy and partial gastrectomy. Six patients had a total
gastrectomy and had a geometric mean of the average total concentra-
tion of 5.3 ± SD 1.35 μmol/L (3.73–8.81; CV% 30.6). Thirteen patients
had a partial gastrectomy and had a geometric mean of the average
total concentration of 7.8 ± SD 1.53 μmol/L (3.81–19.8; CV% 44.9).
4 | DISCUSSION
This study demonstrates that neither the PFS of regorafenib treat-
ment nor the exposure to regorafenib and its pharmacologically active
metabolites changed in patients who underwent gastrectomy. The
results of this study assent that there is no need for dose adjustments
in patients who underwent gastrectomy and are treated with
regorafenib.
To our knowledge, this is the first study to investigate the effect of
gastrectomy on regorafenib exposure and clinical outcome. The pre-
dicted impact of gastric surgery on drug exposure is considered to be
compound specific.25 Therefore, results from other studies exploring
the effect of gastrectomy on drug exposure cannot be extrapolated to
results found in our study. Recently, a study has been published inves-
tigating the effect of an acid reducing agent on regorafenib absorption.
They showed that alterations in gastric pH did not affect regorafenib
exposure.14 However, as seen with imatinib, the potential influence of
gastric transporters, could not be ruled out by the study of de Man
et al.14 In our study, we showed that neither regorafenib exposure
nor PFS was altered in patients who underwent gastrectomy. We
therefore conclude that stomach transporters play no clinically relevant
role in the uptake of regorafenib in the third line GIST population.
The exposure–response relation in GIST patients treated with
regorafenib has not been thoroughly investigated. The phase 1 dose
escalation study by Mross et al.7 demonstrated a dose dependent
reduction in plasma sVEGFR‐2, which might be an indirect marker
for an exposure‐response relationship. Additionally, the frequency of
treatment‐related adverse events increased with higher dose levels.7
In a exposure–response analysis in patients with hepatocellular carci-
noma a trend, although not significant, towards a shorter overall
FIGURE 1 Kaplan–Meier progression free survival analysis after gastric surgery
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survival in the low exposure group was seen when compared to the
patients with a medium or high exposure.26,27 In our subanalysis, the
sum exposure to regorafenib and its pharmacological active metabo-
lites in the total gastrectomy group was slightly lower compared to
the no or nonsignificant gastrectomy group. On the contrary, the
exposure in the partial gastrectomy group was higher than the expo-
sure in the no or nonsignificant gastrectomy group. The results of this
subanalysis are based on a very small number of patients with a wide
interpatient variability and therefore do not influence our finding that
the type of gastrectomy does not alter regorafenib exposure and PFS.
Hypothetically, toxicity is driven by local or systemic exposure
levels and therefore less systemic toxicity and more GI toxicity would
be expected in the patients with major gastrectomy. The only differ-
ence in drug‐related adverse events reported is hand–foot syndrome,
which is observed more frequently in the patients with major gastrec-
tomy in whom less toxicity would be expected. The number of
patients who reported >grade 2 drug‐related adverse events is limited
and therefore no conclusions can be derived from these data.
The number of patients who had undergone a major gastrectomy
in our study is limited and, as a consequence, has limited statistical
power. Furthermore, the retrospective nature of this study could have
introduced different sources of bias inherent to retrospective analy-
ses. However, the data used in our study are data from a well‐
documented clinical study and the gastrectomy status was recorded
for all patients. In addition, PK data are not prone to be influenced
by patients or physician interventions. Therefore, we believe that
our study contributes to further understanding of the effect of rego-
rafenib in patient with a gastrectomy and on the PK behaviour of
regorafenib in these patients.
In conclusion, GIST patient with a gastrectomy who are treated
with regorafenib have no altered regorafenib exposure and do not
show a difference in PFS. Patients with gastrectomy do not need
upfront adjustments of regorafenib dose.
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